Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
Echo Lake Capital Offers To Acquire Aclarion Inc.
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Aclarion Announces $2.5 Million Stock Repurchase Plan
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Aclarion Announces Agreement with Weill Cornell Medicine
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Aclarion CEO Brent Ness to Attend LSI USA 2026